Protection of INS-1 cells from free fatty acid-induced apoptosis by inhibiting the glycogen synthase kinase-3

Abstract

To examine the role of glycogen synthase kinase 3 (GSK-3) in the apoptosis of pancreatic β-cells to better understand the pathogenesis and to find new approach to the treatment of type 2 diabetes, apoptosis was induced by oleic acid (OA) in INS-1 cells and the activity of GSK-3 was inhibited by LiCl. The PI staining and flow cytometry were employed for the evaluation of apoptosis. The phosphorylation level of GSK-3 was detected by Western blotting. The results showed that OA at 0.4 mmol/L could cause conspicuous apoptosis of INS-1 cells and the activity of GSK-3 was significantly increased. After the treatment with 24 mmol/L of LiCl, a inhibitor of GSK-3, the OA-induced apoptosis of INS-1 cells was lessened and the phosphorylation of GSK-3 was increased remarkably. It is concluded that GSK-3 activation plays an important role in OA-induced apoptosis in pancreatic-cells and inhibition of the GSK-3 activity can effectively protect INS-1 cells from the OA-induced apoptosis. Our study provides a new experimental basis and target for the clinical treatment of type-2 diabetes.

Keywords

glycogen synthase kinase 3 / apoptosis / oleic acid

References

[1] RhodesC. J.. Type 2 diabetes a matter of β-cell life and death?. Science, 2005, 307: 380-384

[2] WredeC. E., DicksonL. M., MelissaK., et al.. Protein kinase B/Akt prevents fatty acid-induced pancreatic-cells (INS-1). Biol Chem, 2002, 277: 49 676-49 684

[3] HiguchiM., OnishiK., MasuyamaN.. The phosphatidylinositol-3 kinase (PI3K)-Akt pathway suppresses neurite branch formation in NGF-treated PC12 cells. Genes Cells, 2003, 8(8): 657-669

[4] JinS., ShenJ. N., WangJ.. Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol Ther, 2007, 26(2): 111

[5] BeurelE., JopeR. S.. The paradoxical pro-and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol, 2006, 79(4): 173-189

[6] Cline G W, Johnson K, Regittnig W et al. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes, 2002,(51):2903–2910

[7] CohenP., GoedertM.. GSK3 inhibitors: development and therapeutic potential for the treatment of disease. Nature Rev Drug Discov, 2004, 3: 479-487

[8] Jope R S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci, 2003,(24):441–443